# A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis

> **NCT01604265** · PHASE3 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 66 (actual)

## Conditions studied

- Multiple Sclerosis
- Neuropathic Pain

## Interventions

- **DRUG:** Placebo
- **DRUG:** Sativex

## Key facts

- **NCT ID:** NCT01604265
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2002-08
- **Final completion:** 2002-08
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2023-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01604265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01604265, "A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01604265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*